Europeiska unionen - svenska - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - immunsuppressiva - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).

Europeiska unionen - svenska - EMA (European Medicines Agency)

glaxosmithkline trading services - mepolizumab - astma - läkemedel mot obstruktiv lungsjukdom, - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. chronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (egpa). hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.

Europeiska unionen - svenska - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenter för dermatit, med undantag av kortikosteroider - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

virbac sa - fipronil - spot-on, lösning - 134 mg - fipronil 134 mg aktiv substans; bensylalkohol hjälpämne; butylhydroxianisol hjälpämne; butylhydroxitoluen hjälpämne - fipronil - hund

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

virbac sa - fipronil - spot-on, lösning - 268 mg - bensylalkohol hjälpämne; butylhydroxitoluen hjälpämne; butylhydroxianisol hjälpämne; fipronil 268 mg aktiv substans - fipronil - hund

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

virbac sa - fipronil - spot-on, lösning - 402 mg - butylhydroxitoluen hjälpämne; bensylalkohol hjälpämne; butylhydroxianisol hjälpämne; fipronil 402 mg aktiv substans - fipronil - hund

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

virbac sa - fipronil - spot-on, lösning - 50 mg - bensylalkohol hjälpämne; butylhydroxitoluen hjälpämne; butylhydroxianisol hjälpämne; fipronil 50 mg aktiv substans - fipronil - katt

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

virbac sa - fipronil - spot-on, lösning - 67 mg - butylhydroxitoluen hjälpämne; butylhydroxianisol hjälpämne; fipronil 67 mg aktiv substans; bensylalkohol hjälpämne - fipronil - hund

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

fresenius kabi ab - natriumklorid - spädningsvätska för parenteral användning - 9 mg/ml - natriumklorid 9 mg aktiv substans - spädningsvätskor och spolvätskor

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

fresenius kabi ab - vatten - spädningsvätska för parenteral användning - vatten aktiv substans - spädningsvätskor och spolvätskor